Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Has Consensus Target Price of $68.60 According to Brokerages

Travere Therapeutics, Inc. (NASDAQ:TVTX) has been given an average rating of “Moderate Buy” by the thirteen research firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and eleven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $68.45.

A number of research analysts have weighed in on the stock. Evercore set a $78.00 price objective on shares of Travere Therapeutics in a report on Monday, August 10th. Piper Sandler reissued an “overweight” rating on shares of Travere Therapeutics in a research note on Monday, August 17th. Leerink Partners dropped their target price on Travere Therapeutics from $78.00 to $67.00 and set an “outperform” rating on the stock in a research report on Thursday. Canaccord Genuity Group lifted their price target on Travere Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Wedbush restated an “outperform” rating and issued a $76.00 price target on shares of Travere Therapeutics in a research note on Tuesday, September 22nd.

Insider Activity at Travere Therapeutics

In other news, insider William E. Rote sold 112,850 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $63.33, for a total value of $7,146,790.50. Following the completion of the sale, the insider directly owned 98,197 shares in the company, valued at $6,218,816.01. The trade was a 53.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher R. Cline sold 50,508 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $62.34, for a total value of $3,148,668.72. Following the transaction, the chief financial officer directly owned 87,508 shares of the company’s stock, valued at approximately $5,455,248.72. The trade was a 36.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,294,029 shares of company stock valued at $79,454,261 in the last ninety days. 4.44% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jupiter Topco LLC acquired a new position in Travere Therapeutics in the 2nd quarter valued at $643,299,000. Bank of America Corp DE purchased a new position in Travere Therapeutics in the 2nd quarter valued at $259,527,000. Assenagon Asset Management S.A. boosted its stake in Travere Therapeutics by 168.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,145,414 shares of the company’s stock worth $67,442,000 after purchasing an additional 718,109 shares during the last quarter. Aberdeen Group plc boosted its stake in Travere Therapeutics by 483.3% during the 3rd quarter. Aberdeen Group plc now owns 728,295 shares of the company’s stock worth $42,882,000 after purchasing an additional 603,440 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in Travere Therapeutics by 50.0% during the 2nd quarter. Wellington Management Group LLP now owns 1,533,080 shares of the company’s stock worth $87,094,000 after purchasing an additional 510,808 shares during the last quarter.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $49.60 on Thursday. The company has a debt-to-equity ratio of 26.72, a current ratio of 3.00 and a quick ratio of 3.99. The stock has a market capitalization of $4.76 billion, a price-to-earnings ratio of -38.45 and a beta of 1.11. The firm’s 50 day simple moving average is $57.40 and its 200-day simple moving average is $47.00. Travere Therapeutics has a 12 month low of $22.59 and a 12 month high of $68.73.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.49). Travere Therapeutics had a negative net margin of 18.66% and a negative return on equity of 185.69%. The firm had revenue of $224.56 million during the quarter, compared to analyst estimates of $195.29 million. During the same quarter in the prior year, the firm earned $0.28 earnings per share. The business’s revenue for the quarter was up 36.2% on a year-over-year basis. Analysts expect that Travere Therapeutics will post -0.90 EPS for the current year.

More Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $72 from $70 and maintained a Buy rating, signaling continued confidence in the shares. Article: Travere Therapeutics Stock Gets Price Target Increase from Canaccord Genuity Group
• Positive Sentiment: HC Wainwright kept its Buy rating and $67 target while raising its earnings forecasts for 2027–2030, including its 2030 EPS estimate to $6.84 from $5.73. The revisions point to stronger expected longer-term earnings.
• Neutral Sentiment: Analyst actions were mixed: Leerink Partners cut its target to $67 from $78 but retained an Outperform rating, while Guggenheim also lowered its target; the report provided no revised figure. Article: Travere Therapeutics Stock Price Target Cut by Guggenheim
• Negative Sentiment: Travere’s latest quarterly results missed sharply on earnings: EPS was a loss of $0.55 versus the expected loss of $0.06. Revenue beat estimates at $224.56 million and rose 36.2% year over year, but the earnings shortfall contributed to reports of a post-results share-price gap down. Article: Travere Therapeutics Shares Gap Down After Earnings Miss

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with an emphasis on serious kidney conditions. The company’s work centers on addressing diseases with limited treatment options and improving outcomes for patients with progressive renal disorders.

Travere’s lead commercial product is FILSPARI (sparsentan), an oral treatment for adults with primary immunoglobulin A nephropathy (IgA nephropathy) who are at risk of disease progression.